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The aim of this study was to estimate the incidence of diabetes mellitus in the Basque Country and 
the risk factors involved in the disease by reassessing an adult population after 7 years of follow‑up. 
In the previous prevalence study, 847 people older than 18 years were randomly selected from all 
over the Basque Country and were invited to answer a medical questionnaire, followed by a physical 
examination and an oral glucose tolerance test. In the reassessment, the same variables were 
collected and the resulting cohort comprised 517 individuals of whom 43 had diabetes at baseline. The 
cumulative incidence of diabetes was 4.64% in 7 years and the raw incidence rate was 6.56 cases/1000 
person‑years (95%CI: 4.11–9.93). Among the incident cases, 59% were undiagnosed. The most 
strongly associated markers by univariate analyses were age > 60 years, dyslipidaemia, prediabetes 
and insulin resistance. We also found association with hypertension, obesity, family history of 
diabetes and low education level. Multivariate analysis adjusted for age and sex showed that a set of 
risk factors assessed together (dyslipidaemia, waist‑to‑hip‑ratio and family history of diabetes) had 
great predictive value (AUC‑ROC = 0.899, 95%CI: 0.846–0.953, p = 0.942), which suggests the need for 
early intervention before the onset of prediabetes.
Abbreviations
IFG  Impaired fasting glucose
IGT  Impaired glucose tolerance
NFG  Normal fasting glucose
NGT  Normal glucose tolerance
WC  Waist circumference
WHR  Waist-to-hip ratio
Diabetes mellitus is a chronic disease with an increasing frequency over the last decade related to the aging popu-
lation and lifestyle changes that promote  obesity1. Based on current data from worldwide studies, the Interna-
tional Diabetes Federation (IDF) estimates that the global number of people with diabetes (aged 18–99 years) will 
increase to 693 million by  20451. This serious pathology has become a priority health problem in the twenty-first 
century according to the World Health Organization (WHO)2. Its growing prevalence is predicted to increase 
the significant social and economic impact resulting from the disease associated  complications2–6. Nevertheless, 
prevention is possible when acting on risk factors and making an early diagnosis and adequate treatment that 
prevent long-term  complications7–9.
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Studies on the diabetes incidence provide more reliable information on the risk factors involved in the 
disease progression compared to the prevalence ones. Therefore, IDF advocates that accurate incidence studies 
should be  made1. Following this recommendation, we have re-evaluated the current health status of the same 
cohort than previously analysed in the diabetes prevalence study carried out during 2010–2012 in the Basque 
 Country10, to determine the incidence of diabetes in our population and the risk factors that are involved in the 
progression of the disease.
Results
The reassessment of the cohort that participated in the previous prevalence study (baseline study) after seven 
years of follow-up, made the determination of diabetes incidence in the Basque Country possible, as well as the 
evaluation of the risk factors involved in the progression of the disease. The baseline characteristics of partici-
pants and non-participants in the present re-examination are shown in Table 1. Except for the obesity (16.8% vs. 
23.0%, p = 0.025) and diabetes percentage (8.4% vs. 14.3%, p = 0.010) that are lower in the group of participants, 
the frequency of the rest of the variables were similar in both groups.
Among the 517 people who agreed to participate in the reassessment, 43 had diabetes at baseline (2010–2012) 
and were excluded from all the diabetes incidence calculations. Thus, the group at risk was established with 
474 people of whom 22 developed diabetes over a period of 7 years. Among the 22 newly diagnosed diabetes 
cases, 13 were not aware about their disease (unknown diabetes). All these undiagnosed cases underwent a 75 g 
OGTT: 5 cases were diagnosed with diabetes by fasting blood glucose, 6 cases by glucose at 120 min and 2 cases 
by both, fasting and 120 min glucose, according to the WHO  criteria11. These data yield a cumulative incidence 
of diabetes of 4.64% in 7 years and a raw incidence rate of 6.56 cases/1000 person-year (95%CI 4.11–9.93). The 
adjusted estimation for age and sex structure of the Spanish population was of 5.37 cases/1000 person-year (95% 
CI 5.35–5.40).
The incidence rates of diabetes according to the variables tested in the study, as well as the OR (95%CI) for 
diabetes resulted from the univariate binomial regression logistic analyses are detailed in Table 2. Although the 
incidence rate was slightly higher in men, the difference between sexes did not reach statistical significance. The 
strongest association with the diabetes progression was found from 60 years of age onwards, dyslipidaemia, pre-
diabetes at baseline and insulin resistance. A statistically significant increase in the incidence rate of diabetes in 
individuals with hypertension, family history of diabetes, low education level and obesity was also found. Other 
analysed variables, such as physical activity or smoking, failed to show any association with diabetes development.
The results of the multivariate binomial logistic regression analyses adjusted for sex and age are shown in 
Table 3. Two different models were proposed to predict diabetes and were based on the inclusion or not of 
variables related to the prediabetes symptoms at baseline. In model A, waist-to-hip ratio and family history of 
diabetes were independently associated with diabetes, together with low HDL-cholesterol and prediabetes at 
baseline. These two last variables were the strongest diabetes progression predictors in this first proposal. Model 
B was built with the same variables than the first one except for those with prediabetes and/or insulin resistance. 
In this second proposal, low HDL-cholesterol was the strongest predictor and together with high triglycerides 
level, waist-to-hip ratio and family history of diabetes, was associated with diabetes. The area under the receiver-
operating-characteristic curve for diabetes was 0.927 (95% CI: 0.891–0.963) in model A and 0.899 (95% CI: 
0.848–0.953) in model B. Both models had adequate goodness-of-fit (p = 0.613 and p = 0.942, respectively).
Table 1.  Baseline characteristics of the population under study (2010–2012). Comparison between non-
participants and participants in the follow-up. Age is shown as median (IQR:  P25–P75). Rest of variables 
is shown as n/total (%) where total is the number of non-participants or participants for each variable, as 
appropriate. Family history of diabetes defined as 1st or 2nd degree relatives with diabetes. Definitions of the 
rest of cardiovascular risk factors are detailed in methods. a Pearson’s Chi-square test. b Mann-Whitney U-test.
Non-participants Participants p-value
Sex (men) 152/330 (46.1%) 226/517 (43.7%) 0.549a
Age (years) 52.7 (37.6–66.6) 52.3 (40.4–63.5) 0.843b
Obesity 77/330 (23.3%) 87/517 (16.8%) 0.025a
Abdominal obesity (WC) 181/330 (54.8%) 265/516 (51.4%) 0.357a
Abdominal obesity (WHR) 81/330 (24.5%) 111/516 (21.5%) 0.345a
Hypertension 157/330 (47.6%) 223/517 (43.1%) 0.231a
High triglycerides level 48/320 (15.0%) 98/510 (19.2%) 0.145a
Low HDL-cholesterol 47/319 (14.7%) 68/507 (13.4%) 0.667a
High LDL-cholesterol 85/316 (26.9%) 154/502 (30.7%) 0.281a
Family history of diabetes 126/305 (41.3%) 222/493 (45.0%) 0.339a
Education level (primary or lower) 115/330 (34.8%) 166/517 (32.1%) 0.453a
Regular exercise (at least once a week) 155/330 (47.0%) 265/517 (51.3%) 0.252a
Smoker (> 1 cigarette/day) 80/330 (24.2%) 121/517 (23.4%) 0.844a
Normoglycaemia 243/322 (75.5%) 411/513 (80.1%) 0.133a
Prediabetes 33/322 (10.2%) 59/513 (11.5%) 0.653a
Diabetes 46/322 (14.3%) 43/513 (8.4%) 0.010a
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Table 2.  Diabetes incidence rates and OR (95% CI) for diabetes according to possible risk factors. People at 
risk were those without diabetes in the prevalence study (2010–2012). Family history of diabetes defined as 
1st or 2nd degree relatives with diabetes. Definitions of the rest of cardiovascular risk factors are detailed in 
methods. OR (95%CI) were calculated for each variable by univariate binomial logistic regression analyses.
People at-risk (n) New DM cases (n) Person-year (n)
Incidence rate/1000 
person-years 
(95%CI) OR (95% CI) p-value
Whole cohort 474 22 3356 6.56 (4.11–9.93) _ _
Sex
Women 282 12 1997 6.01 (3.11–10.50) 1
Men 192 10 1359 7.36 (3.53–13.53) 1.25 (0.53–2.89) 0.611
Age (years)
18–45 114 1 807 1.24 (0.03–6.90) 1
46–60 150 4 1062 3.77 (1.03–9.64) 2.32 (0.42–23.41) 0.348
61–75 150 12 1062 11.30 (5.84–19.74) 6.83 (1.61–63.36) 0.006
 ≥ 76 60 5 425 11.77 (3.82–27.47) 7.5 (1.45–74.4) 0.015
BMI (Kg/m2)
< 25 164 4 1161 3.44 (0.94–8.82) 1
25–30 207 7 1466 4.78 (1.92–9.84) 1.33 (0.42–4.78) 0.631
≥ 30 100 10 708 14.12 (6.77–25.98) 4.14 (1.40–14.33) 0.010
Abdominal obesity (WC)
No 155 4 1097 3.64 (0.99–9.33) 1
Yes 232 16 1643 9.74 (5.57–15.82) 2.57 (0.96–8.44) 0.062
Abdominal obesity (WHR)
No 270 6 1912 3.14 (1.15–6.83) 1
Yes 117 14 828 16.90 (9.24–28.36) 5.7 (2.28–15.84) < 0.001
Hypertension
No 217 5 1536 3.25 (1.06–7.59) 1
Yes 185 16 1310 12.22 (6.98–19.84) 3.76 (1.49–11.10) 0.005
High triglycerides level
No 330 10 2336 4.28 (2.05–7.87) 1
Yes 56 10 396 25.22 (12.09–46.38) 6.89 (2.75–17.32) < 0.001
Low HDL-cholesterol
No 273 3 1933 1.55 (0.32–4.54) 1
Yes 126 18 892 20.18 (11.96–31.89) 13.18 (4.60–50.70) < 0.001
High LDL-cholesterol
No 252 5 1784 2.80 (0.91–6.54) 1
Yes 147 16 1041 15.37 (8.79–24.97) 5.65 (2.22–16.69) < 0.001
Glucose at baseline
NFG and/or NGT 415 10 2938 3.40 (1.63–6.26) 1
Isolated IGT 37 6 262 22.90 (8.41–49.85) 7.97 (2.67–22.29) < 0.001
Isolated IFG 19 4 135 29.74 (8.10–76.13) 11.21 (3.04–36.41) < 0.001
IFG and IGT 3 2 21 94.16 (11.4–340.15) 64.37 (7.89–750.91)  < 0.001
Insulin resistance (HOMA-IR index)
No 279 5 1975 2.53 (0.82–5.91) 1
Yes 106 15 750 19.99 (11.19–32.97) 8.45 (3.28–25.24) < 0.001
Family history of diabetes
No 192 5 1359 3.68 (1.19–8.58) 1
Yes 191 15 1352 11.09 (6.21–18.30) 2.99 (1.17–8.89) 0.021
Education level (primary or lower)
No 273 8 1933 4.14 (1.79–8.16) 1
Yes 114 12 807 14.87 (7.68–25.97) 3.81 (1.56–9.72) 0.003
Regular exercise (at least once a week)
Yes 217 9 1536 5.86 (2.68–11.12) 1
No 170 11 1204 9.14 (4.56–16.35) 1.58 (0.65–3.92) 0.307
Smoker (> 1cigarette/day)
Non-smoker 159 8 1126 7.11 (3.07–14.00) 1
Ex-smoker 163 10 1154 8.67 (4.16–15.94) 1.22 (0.48–3.18) 0.676
Smoker 65 2 460 4.35 (0.53–15.70) 0.70 (0.13–2.63) 0.620
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Apart from the 22 new cases of diabetes, there were 30 new cases of prediabetes, meaning that overall, 52 
people had some glucose metabolism disorder after the follow-up period. In contrast, among the 102 cases with 
any glucose metabolism disturbance in the previous prevalence study, 36 showed an improvement after the reas-
sessment: 31 people had normoglycaemia and five cases with diabetes had improved to prediabetes.
Discussion
The current study, based on a representative sample of the Basque Country, estimates an incidence rate of dia-
betes of 6.56 cases/1000 person-year. The single previous incidence study on diabetes in general population of 
the Basque Country was carried out 20 years  ago12, when a cohort of 594 people without diabetes at baseline 
(> 30 years) was reassessed after a follow-up of 10 years. The estimated raw incidence rate was 7.0 cases/1000 
person-year, a little higher than the current estimation. Considering that in the present analysis the only dif-
ference between participants and non-participants is the lower percentage of obesity among participants (23% 
vs. 17%, p = 0.026) and, as obesity is a major risk factor in the development of diabetes, we could think that 
the current incidence may be underestimated and then, assume that the incidence of diabetes in our area has 
remained stable for 20 years.
It should be noted the difficulty to compare the incidence estimations from different areas due to the vary-
ing procedures among studies. However, the present study focused on a region in northern Spain has followed 
the same methodology than the recently published nationwide study, which tolerates valid comparisons. Our 
estimated incidence of diabetes in the Basque Country adjusted for the age and sex structure of the Spanish 
population is 5.37 cases/1000 person-years (95%CI 5.35–5.40), lower than the recently published data for  Spain13, 
11.6 cases/1000 person-years (95%CI 11.1–12.1). There are few data about the incidence of diabetes in general 
population of different regions in Spain. Despite small differences in the methodology, we could say that the 
incidence rate in our cohort, 6.56 cases/1000 person-year, is lower than that reported in a neighboring region of 
northern  Spain14, 10.8 cases/1000 person-years, and noticeably lower than the estimate for the southern  Spain15, 
19.1 cases/1000 person-years. This fact confirms a heterogeneous distribution of diabetes in the  country16 and 
may be related to the prevalence of obesity which is almost half in the Basque  Country10 compared to southern 
 Spain17, 19% versus 37%, respectively.
Unlike many published studies in which the incidence of diabetes is estimated from questionnaires or by 
reviewing clinical  records18,19, in our study, diabetes was diagnosed in general population on basis of an OGTT 
or with a fasting glucose measurement. This procedure, which was carried out both in the baseline study and 
in the follow-up, allows a more accurate estimation of the incidence of diabetes, since it also includes cases of 
unknown diabetes. In this survey, more than half of the new diabetes cases, 13/22, were not aware about their 
disease. This is a disturbing figure that has not improved since the prevalence study in which the unknown dia-
betes figure accounted for 41% of the diabetes  cases10. The IDF warns that the risk of developing cardiovascular 
events is higher in these people not receiving neither treatment nor preventive  measures20 thereby, it is of great 
importance to perform regular diabetes screening in general population to reduce the number of unknown cases.
As expected, several cardiovascular risk factors such as the age from 60 onwards, dyslipidaemia, hyperten-
sion, obesity and altered WHR, are associated with diabetes in the univariate analyses. However, male sex which 
is widely defined as a risk factor for developing diabetes, does not reach statistical significance in our study, 
probably because of the limited number of new cases detected in our cohort. The strongest association with the 
Table 3.  Multivariate binomial logistic regression models to assess the contribution of different variables in 
diabetes prediction. The starting model A included all variables with p < 0.2 in the univariate analysis. In model 
B, the same variables were included, except for the pre-diabetes status at baseline and the HOMA-IR index. 
The two models were built manually. At each step of the modelling process, we repeatedly removed the variable 
with the highest p-value and we tested the model again until all remaining variables were significant (p < 0.05). 
Age and sex, regardless of their statistical significance, were kept in the final model. Family history of diabetes 
defined as 1st or 2nd degree relatives with diabetes. Definitions of the rest of cardiovascular risk factors are 
detailed in methods.
Model A OR (95% CI) p-value
Sex (Men) 2.02 (0.65–6.43) 0.224
Age 1.01 (0.97–1.06) 0.660
Abdominal obesity (WHR) 3.93 (1.18–14.20) 0.025
Low HDL-cholesterol 6.66 (2.10–27.18) < 0.001
Family history of diabetes 3.61 (1.23–12.47) 0.019
Pre-diabetes 7.04 (2.52–20.59) < 0.001
Model B OR (95% CI) p-value
Sex (Men) 2.68 (0.91–8.26 0.074
Age 1.03 (0.99–1.07) 0.198
Abdominal obesity (WHR) 3.67 (1.19–12.27) 0.024
High triglycerides level 3.55 (1.29–9.77) 0.014
Low HDL cholesterol 7.08 (2.25–28.82) < 0.001
Family history of diabetes 3.01 (1.09–9.48) 0.033
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3016  | https://doi.org/10.1038/s41598-021-82548-y
www.nature.com/scientificreports/
progression of the disease is found with the prediabetes status at baseline which is greater in isolated cases of 
IFG than in isolated cases of IGT, as described in other  reports14,21. This is not an unexpected result considering 
that the metabolic abnormalities underlying both disorders are  different22. Individuals with isolated IFG and 
isolated IGT show similar impairments in insulin action, but those with isolated IFG have a more pronounced 
defect in early insulin secretion and, additionally, have clear abnormalities in hepatic glucose regulation. More 
severe metabolic abnormalities are present in individuals with combined IFG and IGT, being the most strongly 
associated disorder with the progression of diabetes in our cohort.
All tested variables in the univariate analyses were used to build two multivariate models. The model includ-
ing variables related to the symptoms of prediabetes at baseline has the highest predictive capacity, but the other 
has a high predictive value too. This second model supports the importance of abdominal obesity, dyslipidaemia 
and the genetic component in the etiopathogenesis of the disease and suggests the need for early intervention 
before the onset of prediabetes to prevent the progression of the pathology.
Specially worth mentioning is that in our cohort, 30% of people with some glucose metabolism disorder 
at baseline reverted to normoglycaemia after 7 years of follow-up. This figure is similar to that found in other 
 studies8,23. This percentage of reversion could be due to the less strict criteria used in epidemiology for the diagno-
sis of diabetes, which results in false positives. However, it should not be ruled out that weight loss may contribute 
to improving glucose metabolism, highlighting the potential of non-pharmacological prevention  strategies9,24,25.
It could be considered a limitation of the study that 33% of people of the original cohort were lost to follow-up. 
However, the participation of those contacted reached 85% and few differences were found between participants 
and non-participants, minimizing any possible selection bias. Additionally, only 19% of participants refused the 
blood analysis and completed exclusively the basic questionnaire for diagnosis. The main strengths of our study 
are, first, the methodology that has allowed valid comparisons with recently published data at national level, and 
second, the sampling. Indeed, this is the first study carried out on the general population in different geographi-
cal areas of the Basque Country and therefore has a more accurate estimate of the incidence of diabetes in the 
Basque population, including also undiagnosed cases.
In summary, the incidence rate of diabetes in the Basque Country remains stable over time and lower than 
those reported from other Spanish regions probably due to the lower percentage of obesity. Furthermore, our 
results show that the criteria for identifying the population at high risk of developing diabetes should not be 
based exclusively on the presence of prediabetes, but the predictive value of a set of risk factors assessed together, 
such as dyslipidaemia, waist-to-hip ratio and family history of diabetes support enough evidence to approach a 
lifestyle intervention that avoids the progression of the disease.
Patients and methods
Population. A cross-sectional, cluster sampling design study was carried out during 2010–2012 to estimate 
the prevalence of diabetes in the Basque  Country10. The Basque Country is a region of 7234 km2 in northern 
Spain with a population of 2,178,048 inhabitants, mostly Caucasian. Adults (≥ 18 years) were randomly selected 
from 20 public health centres representative of the Basque Country. A total of 847 people completed the baseline 
study. This cohort was reassessed in 2018–2019 after 7.1 years of follow-up (IQR 6.5–7.6). All individuals who 
took part in the baseline study (2010–2012) were invited to attend another clinical examination by letter and 
phone call to assist to medical centre. Among the 847 initial cases, 238 (loss to follow-up rate 28%) were not 
available (did not answer the phone, moved to another residence outside the area of interest or died), another 
25 were excluded due to study protocol (hospitalized, severe disease, surgical intervention and pregnancy or 
recently delivered women) and 67 refused to participate. The resulting cohort consisted of 517 individuals (par-
ticipation rate 85%) of whom 43 had diabetes at baseline, 367 (71%) underwent a 75 g OGTT, 52 (10%) accepted 
a fasting blood analysis and 98 (19%) only completed a basic questionnaire (Fig. 1).
The research was carried out in accordance with the Declaration of Helsinki (2008) of the World Medical 
Association. The study was approved by our local ethic committee, CEIC-E (Comité Etico de Investigación 
Clínica de Euskadi) and informed consent was obtained from all the participants.
Procedures. The same methodology was used for both the prevalence and the reassessment study. In sum-
mary, all participants were invited to attend a medical examination at their health centre with a nurse specially 
trained for this project. Participants were required to answer a questionnaire on personal and family medical 
history and lifestyle. Physical examination included blood pressure (Hem-703 CP, Omron, Barcelona, Spain), 
weight, height, waist and hip circumferences measurements and, finally, a 75 g OGTT was also performed. The 
OGTT was not completed in people with capillary blood glucose measurements > 9.9  mmol/L (One Touch 
Select Plus, Lifescan, Johnson & Johnson, S.A., Madrid, Spain), or in individuals who had previous diabetes. 
When an OGTT was not possible, a fasting glucose analysis was carried out. People who did not want to fully 
participate in the study were requested to answer a basic questionnaire in order to collect information about 
pharmacological treatment (to determine the existence of clinical diabetes, hypertension or dyslipidaemia in 
treatment), the kind of diet they were following and self-reported weight.
All samples were centrifuged in situ 15 min after each blood extraction and transported daily for biochemi-
cal parameters analyses to the Clinical Biochemistry Laboratory of the Cruces University Hospital. Glucose, 
HDL-cholesterol and triglycerides were analysed in the ADVIA 2400 Chemistry analyser (Siemens Healthcare 
Diagnostics Inc, Deerfield, IL, USA), according to the corresponding reagent protocols. The LDL-cholesterol was 
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Definition of cardiovascular risk factors. Diabetes and other categories of glucose metabolism disor-
ders were classified according to the WHO  criteria11. Diagnostic values for blood venous fasting glucose: NFG 
(Normal fasting glucose) < 6.1 mmol/L; IFG (Impaired fasting glucose) 6.1–7.0 mmol/L, Diabetes ≥ 7.0 mmol/L. 
Diagnostic values for blood venous glucose concentration at 120 min (75 g OGTT): NGT (Normal glucose toler-
ance) < 7.8 mmol/L; IGT (Impaired glucose tolerance) 7.8–11.1 mmol/L; Diabetes ≥ 11.1 mmol/L. People with 
isolated IFG or IGT and those with both disorders (IFG + IGT) were considered to have prediabetes. Insulin 
resistance was defined as homeostasis model assessment for insulin resistance (HOMA-IR) higher than  three26.
The following variables, equally considered in baseline study, were also analysed: obesity defined as 
BMI ≥ 30 kg/m2; abdominal obesity defined as waist circumference (WC ≥ 94 cm in men and ≥ 80 cm in 
women) or waist-to-hip-ratio (WHR > 1 in men and > 0.85 in women); Hypertension defined as systolic pres-
sure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg or patient under antihypertensive treatment; High LDL-
cholesterol defined as values ≥ 3.9 mmol/L or patient under lipid-lowering treatment; High Triglycerides level 
defined as values ≥ 1.7 mmol/L; Low HDL-cholesterol defined as values < 1.03 mmol/L in men and < 1.29 mmol/L 
in  women27.
Statistical analysis. Qualitative variables were described as frequencies and percentages, and non-para-
metric quantitative variables as median and interquartile range (IQR:  P25–P75). For comparisons, Chi-square 
Figure 1.  Participation flow chart.
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test and Mann–Whitney U-test were applied as appropriate in each case. Participants with missing data in the 
variable of interest were excluded for statistical analysis.
A univariate binomial logistic regression model was performed to evaluate the association between several 
variables and diabetes. Variables with clinical relevance and p-values < 0.2 were then included in a multivariate 
binomial logistic regression model to assess the contribution of different variables in diabetes prediction. Two 
models were tested. The starting model A included all variables with p < 0.2 in the univariate analysis. In the 
model B, the same variables were included, except for the pre-diabetes status at baseline and the HOMA IR 
index. The two models were built manually. At each step of the modelling process, we repeatedly eliminated the 
variable with the highest p-value and we tested the model again until all remaining variables were significant 
(p < 0.05). Age and sex were kept in the final model regardless of their statistical significance because they are 
recognized predictors of the development of diabetes. Results were expressed as odds ratio (OR) and 95% confi-
dent interval (95% CI). Firth’s method was applied in order to reduce the bias of maximum likelihood estimates 
due to rare events.
To compare the discrimination power of the two models (ability of the model to separate individuals who 
will develop diabetes from those who will not) the area under the receiver operating characteristic (AUC–ROC) 
curves and their 95% confidence intervals (95%CI) were calculated using standard techniques. The model with 
higher AUC–ROC curve is considered to have better discrimination. The Hosmer–Lemeshow test was assessed 
to describe the degree of adjustment between the predictions estimated by the model and the observed results 
(goodness-of-fit). The test indicates a good fit if the result is not significant, indicating that there are no statisti-
cally significant differences between the observed and expected values.
The incidence rates of diabetes in the cohort and according to the studied variables were calculated as numbers 
of events/person-time at risk for diabetes (people at risk were those without diabetes in the previous prevalence 
study). A constant incidence over time was assumed and was expressed per 1000 person-years. To enable com-
parisons with the national study, the estimation of the population incidence was adjusted for sex and age by 
direct method using the Spanish population as reference.
Statistical analyses were performed using R software version 4.0.1 (R Foundation for Statistical Computing). 
Results were considered statistically significant when p < 0.05.
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